Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 3.931
Filter
1.
J Infect Public Health ; 17(10): 102537, 2024 Oct.
Article in English | MEDLINE | ID: mdl-39255545

ABSTRACT

BACKGROUND: Serodiagnosis of TORCH infections should be performed in pre-pregnancy and reproductive-age women to prevent vertical transmission. Herein, we conducted a 5-year cross-sectional retrospective study in childbearing age women to provide prevalence data. Also, stratifying the cohort into three age groups, we identified those most susceptible to acute TORCH infections. METHODS: Between 2019 and 2023, serum samples from 2286 childbearing age women attending the "R. Dulbecco" University Hospital of Catanzaro were collected. Screening for TORCH pathogens, such as: Toxoplasma gondii (TOX), Cytomegalovirus (CMV), Rubella Virus (RUB), Parvovirus B19 (ParvoB19), Herpes Simplex Virus types 1 and 2 (HSV1, HSV2) and Treponema pallidum was carried out using serological tests. Chemiluminescent immunoassay was performed to detect TOX, CMV and ParvoB19 Immunoglobulin M (IgM) and Immunoglobulin G (IgG) antibodies, while Enzyme Linked Fluorescent Assay was performed to detect RUB IgM and IgG antibodies and CMV and TOX IgG Avidity. Enzyme Linked Immunosorbent Assay was performed to detect HSV1 IgG, HSV2 IgG, HSV1/2 IgM, T. pallidum total antibodies and RUB IgG Avidity. Binomial logistic regression models were developed to compare seroprevalence rates among different age groups. RESULTS: The highest immunological protection was observed for RUB infection (87 %), probably associated with vaccination practice, followed by HSV1 and CMV (82 % and 63 %). The 16-25 year age group results as the most susceptible to acute infections as demonstrated by odds of CMV IgM positivity (primary infection) which decreased with age. CONCLUSIONS: The TORCH serological screening program should be implemented in women before pregnancy to formulate strategies for serological screening of childbearing age women and guiding clinicians in making decisions.


Subject(s)
Toxoplasmosis , Humans , Female , Cross-Sectional Studies , Retrospective Studies , Adult , Seroepidemiologic Studies , Young Adult , Adolescent , Toxoplasmosis/epidemiology , Middle Aged , Immunoglobulin M/blood , Antibodies, Viral/blood , Immunoglobulin G/blood , Age Factors , Pregnancy , Rubella/epidemiology , Rubella/immunology , Disease Susceptibility , Prevalence , Toxoplasma/immunology , Parvovirus B19, Human/immunology , Treponema pallidum/immunology , Herpes Simplex/epidemiology , Cytomegalovirus Infections/epidemiology , Rubella virus/immunology , Antibodies, Bacterial/blood , Herpesvirus 1, Human/immunology
2.
Zhonghua Yu Fang Yi Xue Za Zhi ; 58(9): 1318-1323, 2024 Sep 06.
Article in Chinese | MEDLINE | ID: mdl-39290011

ABSTRACT

Objective: To analyze the results of serum IgM antibody and viral nucleic acid testing in measles and rubella cases in China from 2014 to 2023. Methods: Surveillance data on measles and rubella during 2014-2023 were obtained from the Chinese Disease Prevention and Control Information System, and cases that underwent measles/rubella IgM antibody testing and viral nucleic acid testing were included in the study. Information on the number of cases, vaccination status, and laboratory test results was collected, and laboratory test results were compared among cases with different times of rash or onset and different doses of vaccination. Results: From 2014 to 2023, the total number of measles and rubella surveillance cases was 581 746, and the number of measles and rubella cases that underwent both IgM antibody and viral nucleic acid testing was 39 124 and 21 766, respectively, with a double-positive rate of IgM antibody and viral nucleic acid testing of 63.73% (for measles) and 41.68% (for rubella). The single-positive rate for IgM antibody was 21.12% (for measles) and 27.15% (for rubella). The single-positive rate for viral nucleic acid tests was 13.84% (for measles) and 28.19% (for rubella). According to different days of rash or onset (0-3, 4-5, 6-10 and >10), samples of 24 629 (62.95%) measles cases and 15 785 (72.52%) rubella cases were from within 3 days of rash or onset, and the single positive rate of viral nucleic acid detection was 16.90% (for measles) and 32.07% (for rubella). The single positive rate of IgM antibody increased gradually with the time of onset (measles: χ2trend=314.098, P<0.001, rubella: χ2trend=763.846, P<0.001), and reached 31.66% (for measles) and 53.12% (for rubella) after 10 days of rash or onset. Depending on the number of vaccination doses (1, 2,≥3), the single positive rate of viral nucleic acid detection ranged from 12.93% to 20.29% (for measles) and from 25.30% to 27.88% (for rubella). The single positive rate of IgM antibody detection ranged from 36.89% to 47.47% (for measles) and from 22.81 to 41.15% (for rubella). Conclusions: Combined testing of serum IgM antibody and viral nucleic acids could facilitate laboratory confirmation of measles and rubella cases and was also important for measles and rubella elimination efforts.


Subject(s)
Antibodies, Viral , Immunoglobulin M , Measles , Rubella , Humans , Immunoglobulin M/blood , Rubella/epidemiology , Rubella/blood , Measles/epidemiology , Measles/blood , China/epidemiology , Antibodies, Viral/blood , Rubella virus/immunology , Child
4.
Vaccine ; 42(24): 126077, 2024 Oct 24.
Article in English | MEDLINE | ID: mdl-38960788

ABSTRACT

BACKGROUND: India aims to eliminate rubella and congenital rubella syndrome (CRS) by 2023. We conducted serosurveys among pregnant women to monitor the trend of rubella immunity and estimate the CRS burden in India following a nationwide measles and rubella vaccination campaign. METHODS: We surveyed pregnant women at 13 sentinel sites across India from Aug to Oct 2022 to estimate seroprevalence of rubella IgG antibodies. Using age-specific seroprevalence data from serosurveys conducted during 2017/2019 (prior to and during the vaccination campaign) and 2022 surveys (after the vaccination campaign), we developed force of infection (FOI) models and estimated incidence and burden of CRS. RESULTS: In 2022, rubella seroprevalence was 85.2% (95% CI: 84.0, 86.2). Among 10 sites which participated in both rounds of serosurveys, the seroprevalence was not different between the two periods (pooled prevalence during 2017/2019: 83.5%, 95% CI: 82.1, 84.8; prevalence during 2022: 85.1%, 95% CI: 83.8, 86.3). The estimated annual incidence of CRS during 2017/2019 in India was 218.3 (95% CI: 209.7, 226.5) per 100, 000 livebirths, resulting in 47,120 (95% CI: 45,260, 48,875) cases of CRS every year. After measles-rubella (MR) vaccination campaign, the estimated incidence of CRS declined to 5.3 (95% CI: 0, 21.2) per 100,000 livebirths, resulting in 1141 (95% CI: 0, 4,569) cases of CRS during the post MR-vaccination campaign period. CONCLUSION: The incidence of CRS in India has substantially decreased following the nationwide MR vaccination campaign. About 15% of women in childbearing age in India lack immunity to rubella and hence susceptible to rubella infection. Since there are no routine rubella vaccination opportunities for this age group under the national immunization program, it is imperative to maintain high rates of rubella vaccination among children to prevent rubella virus exposure among women of childbearing age susceptible for rubella.


Subject(s)
Antibodies, Viral , Rubella Syndrome, Congenital , Rubella Vaccine , Rubella , Humans , Female , India/epidemiology , Rubella Syndrome, Congenital/epidemiology , Rubella Syndrome, Congenital/prevention & control , Seroepidemiologic Studies , Pregnancy , Rubella/epidemiology , Rubella/prevention & control , Rubella/immunology , Adult , Young Adult , Adolescent , Antibodies, Viral/blood , Incidence , Rubella Vaccine/immunology , Rubella Vaccine/administration & dosage , Immunization Programs , Prevalence , Immunoglobulin G/blood , Vaccination , Pregnancy Complications, Infectious/epidemiology , Pregnancy Complications, Infectious/immunology , Pregnancy Complications, Infectious/prevention & control , Rubella virus/immunology
5.
Eur J Neurol ; 31(10): e16387, 2024 Oct.
Article in English | MEDLINE | ID: mdl-39023088

ABSTRACT

BACKGROUND: Multiple sclerosis (MS) is a demyelinating disease affecting millions of people worldwide. Hereditary susceptibility and environmental factors contribute to disease risk. Infection with Epstein-Barr virus (EBV) and human herpesvirus 6A (HHV-6A) have previously been associated with MS risk. Other neurotropic viruses, such as rubella virus (RV), are possible candidates in MS aetiopathogenesis, but previous results are limited and conflicting. METHODS: In this nested case-control study of biobank samples in a Swedish cohort, we analysed the serological response towards RV before the clinical onset of MS with a bead-based multiplex assay in subjects vaccinated and unvaccinated towards RV. The association between RV seropositivity and MS risk was analysed with conditional logistic regression. RESULTS: Seropositivity towards RV was associated with an increased risk of MS for unvaccinated subjects, even when adjusting for plausible confounders including EBV, HHV-6A, cytomegalovirus and vitamin D (adjusted odds ratio [AOR] = 4.0, 95% confidence interval [CI] 1.8-8.8). Cases also had stronger antibody reactivity towards rubella than controls, which was not seen for other neurotropic viruses such as herpes simplex or varicella zoster. Furthermore, we observed an association between RV seropositivity and MS in vaccinated subjects. However, this association was not significant when adjusting for the aforementioned confounders (AOR = 1.7, 95% CI 1.0-2.9). CONCLUSIONS: To our knowledge, these are the first reported associations between early RV seropositivity and later MS development. This suggests a broadening of the virus hypothesis in MS aetiology, where molecular mimicry between rubella epitopes and human central nervous system molecules could be an attractive possible mechanism.


Subject(s)
Multiple Sclerosis , Rubella virus , Rubella , Humans , Multiple Sclerosis/epidemiology , Multiple Sclerosis/immunology , Multiple Sclerosis/etiology , Multiple Sclerosis/blood , Male , Female , Rubella virus/immunology , Case-Control Studies , Middle Aged , Adult , Risk Factors , Rubella/immunology , Rubella/epidemiology , Antibodies, Viral/blood , Vaccination , Sweden/epidemiology , Rubella Vaccine/immunology , Cohort Studies , Herpesvirus 6, Human/immunology , Aged
6.
Talanta ; 278: 126470, 2024 Oct 01.
Article in English | MEDLINE | ID: mdl-38996565

ABSTRACT

The Rubella virus (RUBV) is a highly contagious pathogen classified within the rubivirus genus, primarily infecting humans and transmitted via airborne routes. RUBV infection generally manifests as a mild illness reminiscent of measles. However, when affecting pregnant women, it can lead to a severe condition known as congenital rubella syndrome (CRS). Rubella infection could be also associated with joint pain, arthritis, and neurological disorders. Determination of Rubella immunity and diagnosis conventionally involve the Hemagglutination Inhibition (HI) test or the Enzyme-Linked Immunosorbent Assay (ELISA). In this study, we describe the selection and characterization of specific aptamers targeting the Rubella virus by using the process of Systematic Evolution of Ligands by EXponantial enrichment (SELEX). The Binding affinity studies have shown that the two aptamers; R-7 and R-5 display the lowest dissociation constants (Kd) of 6.58 nM and 19.05 nM, respectively. Then, R-7 aptamer was modified with a thiol group to enable its immobilization on screen-printed gold electrodes for the Rubella virus aptasensing. The label-free electrochemical detection was achieved using square wave voltammetry (SWV). The designed aptasensor has shown an excellent performance in detecting the Rubella virus within the range of 0.0005 ng/ml to 1000 ng/ml antigen and a limit of detection (LOD) of 0.00015 ng/ml. Selectivity studies were also performed against other viral antigens and serum proteins. Finally, the biosensor applicability was successfully demonstrated in spiked serum samples.


Subject(s)
Aptamers, Nucleotide , Biosensing Techniques , Electrochemical Techniques , Rubella virus , Rubella virus/chemistry , Rubella virus/isolation & purification , Rubella virus/immunology , Aptamers, Nucleotide/chemistry , Biosensing Techniques/methods , Electrochemical Techniques/methods , SELEX Aptamer Technique , Humans , Electrodes , Limit of Detection , Gold/chemistry
8.
J Affect Disord ; 361: 82-90, 2024 Sep 15.
Article in English | MEDLINE | ID: mdl-38844171

ABSTRACT

BACKGROUND AND AIM: Immunity alterations have been observed in bipolar disorder (BD). However, whether serum positivity of antibodies to Toxoplasma gondii (T gondii), rubella, and cytomegalovirus (CMV) shared clinical relevance with BD, remains controversial. This study aimed to investigate this association. METHODS: Antibody seropositivity of IgM and IgG to T gondii, rubella virus, and CMV of females with BD and controls was extracted based on medical records from January 2018 to January 2023. Family history, type of BD, onset age, and psychotic symptom history were also collected. RESULTS: 585 individuals with BD and 800 healthy controls were involved. Individuals with BD revealed a lower positive rate of T gondii IgG in the 10-20 aged group (OR = 0.10), and a higher positive rate of rubella IgG in the 10-20 (OR = 5.44) and 20-30 aged group (OR = 3.15). BD with family history preferred a higher positive rate of T gondii IgG (OR = 24.00). Type-I BD owned a decreased positive rate of rubella IgG (OR = 0.37) and an elevated positive rate of CMV IgG (OR = 2.12) compared to type-II BD, while BD with early onset showed contrast results compared to BD without early onset (Rubella IgG, OR = 2.54; CMV IgG, OR = 0.26). BD with psychotic symptom history displayed a lower positive rate of rubella IgG (OR = 0.50). LIMITATIONS: Absence of male evidence and control of socioeconomic status and environmental exposure. CONCLUSIONS: Differential antibody seropositive rates of T gondii, rubella, and cytomegalovirus in BD were observed.


Subject(s)
Antibodies, Protozoan , Antibodies, Viral , Bipolar Disorder , Cytomegalovirus , Immunoglobulin G , Immunoglobulin M , Rubella virus , Toxoplasma , Humans , Bipolar Disorder/immunology , Bipolar Disorder/blood , Female , Toxoplasma/immunology , Adult , Rubella virus/immunology , Cytomegalovirus/immunology , Cross-Sectional Studies , Antibodies, Viral/blood , Young Adult , Immunoglobulin G/blood , Antibodies, Protozoan/blood , Adolescent , Middle Aged , Immunoglobulin M/blood , Child , Toxoplasmosis/immunology , Toxoplasmosis/blood , Rubella/immunology , Cytomegalovirus Infections/immunology
9.
Methods Mol Biol ; 2808: 225-246, 2024.
Article in English | MEDLINE | ID: mdl-38743374

ABSTRACT

There is increasing interest in evaluating antibody responses to multiple antigen targets in a single assay. Immunity to measles and rubella are often evaluated together because immunity is provided through combined vaccines and because routine immunization efforts and surveillance for measles and rubella pathogens are combined in many countries. The multiplex bead assay (MBA) also known as the multiplex immunoassay (MIA) described here combines the measurement of measles- and rubella-specific IgG antibodies in serum quantitatively according to international serum standards and has been successfully utilized in integrated serological surveillance.


Subject(s)
Antibodies, Viral , Immunoglobulin G , Measles , Rubella , Rubella/immunology , Rubella/epidemiology , Rubella/diagnosis , Rubella/blood , Measles/immunology , Measles/epidemiology , Measles/blood , Measles/diagnosis , Humans , Antibodies, Viral/blood , Antibodies, Viral/immunology , Immunoglobulin G/blood , Immunoglobulin G/immunology , Immunoassay/methods , Rubella virus/immunology , Measles virus/immunology , Serologic Tests/methods
10.
J Virol Methods ; 327: 114947, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38703833

ABSTRACT

Rubella virus infection during early pregnancy sometimes causes severe birth defects termed congenital rubella syndrome. Although there are safe and effective live-attenuated vaccines, rubella has only been certified as eliminated in the Americas within the six World Health Organization regions. Rubella remains an endemic disease in many regions, and outbreaks occur wherever population immunity is insufficient. There are two main methods for diagnosis of rubella: detection of anti-rubella IgM antibodies by enzyme immunoassay and detection of the viral genome by real-time RT-PCR. Both of these methods require substantial time and effort. In the present study, a rapid rubella detection assay using real-time fluorescent reverse transcription loop-mediated isothermal amplification with quenching primers was developed. The time required for the new assay was one-half that required for a real-time RT-PCR assay. The assay had 93.6% positive percent agreement and 100% negative percent agreement for clinical specimens compared with the real-time RT-PCR assay. The new assay is considered useful for diagnosis of rubella in areas where rubella is endemic.


Subject(s)
DNA Primers , Nucleic Acid Amplification Techniques , Rubella virus , Rubella , Rubella virus/genetics , Rubella virus/isolation & purification , Rubella/diagnosis , Rubella/virology , Humans , Nucleic Acid Amplification Techniques/methods , DNA Primers/genetics , Sensitivity and Specificity , Molecular Diagnostic Techniques/methods , Time Factors , Female
11.
Reprod Sci ; 31(9): 2877-2884, 2024 09.
Article in English | MEDLINE | ID: mdl-38630173

ABSTRACT

Serological screening for TORCH(Toxoplasma gondii [TOX], Rubella virus [RV], Cytomegalovirus [CMV], and Herpes simplex virus [HSV]) infections is an effective method for preventing congenital infections caused by TORCH pathogens.In this study, we retrospectively analyzed the characteristics of TORCH infections in 17,807 infertile women of childbearing age in northwest China.We conducted serological detection of TORCH-pathogen-specific IgM and IgG antibodies. The seroprevalence of TORCH infections was statistically analyzed by applying χ2 and Fisher exact-probability tests to evaluate the differences among ages and across quarters of the year. The overall IgM/IgG seroprevalences of TOX, RV, CMV, HSV-1, and HSV-2 were 0.46/3.4%, 0.77/84.93%, 0.68/97.54%, 1.2/82.83%, and 0.62/10.04%, respectively. The positive rates for RV-IgM in women ≥ 40 years old were significantly higher than those for women 25-39 (P < 0.05) years of age. The seroprevalence of HSV1-IgM was higher in the third and fourth quarters of the year (seasons) (P < 0.001), and the seroprevalence of CMV-IgG was statistically significant between differences quarters (P = 0.017), and the seroprevalence of CMV-IgG in the first quarter was lower than that in the third and fourth quarters (Bonferroni correction, P = 0.009 > 0.0083), suggesting no statistically significant difference between the latter two groups. This study showed that in northwestern China the risk of acquiring primary infection by a TORCH pathogen among infertile women of childbearing age were still high, especially Toxoplasma gondii and Herpesvirus type 2 infection. Therefore, effective prevention strategies that include serological screening for TORCH should be implemented.


Subject(s)
Antibodies, Viral , Cytomegalovirus Infections , Herpes Simplex , Infertility, Female , Rubella , Toxoplasmosis , Humans , Female , China/epidemiology , Adult , Toxoplasmosis/epidemiology , Toxoplasmosis/diagnosis , Toxoplasmosis/blood , Seroepidemiologic Studies , Cytomegalovirus Infections/epidemiology , Cytomegalovirus Infections/diagnosis , Cytomegalovirus Infections/blood , Cytomegalovirus Infections/immunology , Infertility, Female/epidemiology , Infertility, Female/blood , Infertility, Female/immunology , Infertility, Female/diagnosis , Rubella/epidemiology , Rubella/diagnosis , Rubella/immunology , Retrospective Studies , Herpes Simplex/epidemiology , Herpes Simplex/diagnosis , Herpes Simplex/blood , Antibodies, Viral/blood , Young Adult , Toxoplasma/immunology , Cytomegalovirus/immunology , Cytomegalovirus/isolation & purification , Immunoglobulin M/blood , Rubella virus/immunology , Immunoglobulin G/blood , Middle Aged , Antibodies, Protozoan/blood , Serologic Tests , Herpesvirus 1, Human/immunology , Herpesvirus 1, Human/isolation & purification
12.
Front Immunol ; 15: 1366840, 2024.
Article in English | MEDLINE | ID: mdl-38680488

ABSTRACT

Rubella virus-associated granulomas commonly occur in immunocompromised individuals, exhibiting a diverse range of clinical presentations. These manifestations can vary from predominantly superficial cutaneous plaques or nonulcerative nodules to more severe deep ulcerative lesions, often accompanied by extensive necrosis and significant tissue destruction. TAP1 deficiency, an exceedingly rare primary immune-deficiency disorder, presents with severe chronic sino-pulmonary infection and cutaneous granulomas. This report highlights the occurrence of rubella virus-associated cutaneous granulomas in patients with TAP1 deficiency. Notably, the pathogenic mutation responsible for TAP1 deficiency stems from a novel genetic alteration that has not been previously reported. This novel observation holds potential significance for the field of diagnosis and investigative efforts in the context of immunodeficiency disorders.


Subject(s)
ATP Binding Cassette Transporter, Subfamily B, Member 2 , Granuloma , Rubella virus , Humans , Granuloma/etiology , Granuloma/virology , Rubella virus/genetics , ATP Binding Cassette Transporter, Subfamily B, Member 2/deficiency , ATP Binding Cassette Transporter, Subfamily B, Member 2/genetics , Rubella/diagnosis , Rubella/immunology , Rubella/complications , Male , Mutation , Adult , Skin Diseases/etiology , Skin Diseases/virology , Female , Skin/pathology , Skin/virology
13.
Int J Infect Dis ; 144: 107053, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38641317

ABSTRACT

BACKGROUND: Vietnam continues to have measles and rubella outbreaks following supplementary immunization activities (SIA) and routine immunization despite both having high reported coverage. To evaluate immunization activities, age-specific immunity against measles and rubella, and the number of averted Congenital Rubella Syndrome (CRS) cases, must be estimated. METHODS: Dried blood spots were collected from 2091 randomly selected individuals aged 1-39 years. Measles and rubella virus-specific immunoglobulin G (IgG) were measured by enzyme immunoassay. Results were considered positive at ≥120 mIU/mL for measles and ≥10 IU/mL for rubella. The number of CRS cases averted by immunization since 2014 were estimated using mathematical modelling. RESULTS: Overall IgG seroprevalence was 99.7% (95%CI: 99.2-99.9) for measles and 83.6% (95%CI: 79.3-87.1) for rubella. Rubella IgG seroprevalence was higher among age groups targeted in the SIA than in non-targeted young adults (95.4% [95%CI: 92.9-97.0] vs 72.4% [95%CI: 63.1-80.1]; P < 0.001). The estimated number of CRS cases averted in 2019 by immunization activities since 2014 ranged from 126 (95%CI: 0-460) to 883 (95%CI: 0-2271) depending on the assumed postvaccination reduction in the force of infection. CONCLUSIONS: The results suggest the SIA was effective, while young adults born before 1998 who remain unprotected for rubella require further vaccination.


Subject(s)
Antibodies, Viral , Immunoglobulin G , Measles , Rubella , Humans , Immunoglobulin G/blood , Measles/epidemiology , Measles/prevention & control , Measles/immunology , Adolescent , Child, Preschool , Child , Rubella/epidemiology , Rubella/immunology , Rubella/prevention & control , Adult , Male , Seroepidemiologic Studies , Female , Young Adult , Infant , Antibodies, Viral/blood , Models, Theoretical , Rubella Vaccine/immunology , Rubella Vaccine/administration & dosage , Rubella virus/immunology , Prevalence , Measles Vaccine/immunology , Measles Vaccine/administration & dosage , Age Factors , Vaccination , Immunization Programs , Rubella Syndrome, Congenital/epidemiology , Rubella Syndrome, Congenital/prevention & control , Rubella Syndrome, Congenital/immunology
14.
Eur J Paediatr Neurol ; 50: 51-56, 2024 May.
Article in English | MEDLINE | ID: mdl-38636242

ABSTRACT

BACKGROUND: Multiple sclerosis (MS) is a chronic inflammatory and demyelinating disease of the CNS. An intrathecal IgM synthesis is associated with a more rapid progression of MS and the intrathecal immune response to measles -, rubella -and varicella zoster virus (MRZR) which, if present, increases the likelihood of a diagnosis of MS in adults. OBJECTIVE: To evaluate the frequency of an intrathecal IgM synthesis and MRZR in children with MS. MethodsChildren with MS and a data set including clinical and treatment history, MRI at onset, in addition to a CSF analysis, and determination of antibody index (AI) of measles, rubella, and zoster antibodies, were eligible. The presence of an intrathecal IgM synthesis and/or a positive MRZ reaction were compared to biomarkers of a more progressive disease course. RESULTS: In 75 children with MS, OCBs were present in 93.3 %). 49,2 % experienced their first relapse within 6 months. 50.7 % had a total lesion load of more than 10 lesions in the first brain MRI. Spinal lesions were identified in 64 %. 23.5 % had a positive MRZR and 40.3 % an intrathecal IgM synthesis. No significant associations were detected between the presence of an intrathecal IgM synthesis and MRZR and parameters including the relapse rate in the first two years. CONCLUSION: An intrathecal IgM synthesis and a positive MRZR are found in a subset of MS children but are not associated with markers associated with a poor prognosis.


Subject(s)
Immunoglobulin M , Magnetic Resonance Imaging , Multiple Sclerosis , Humans , Male , Immunoglobulin M/cerebrospinal fluid , Child , Female , Multiple Sclerosis/diagnostic imaging , Multiple Sclerosis/immunology , Multiple Sclerosis/cerebrospinal fluid , Adolescent , Herpesvirus 3, Human/immunology , Antibodies, Viral/cerebrospinal fluid , Antibodies, Viral/blood , Child, Preschool , Measles virus/immunology , Rubella virus/immunology , Disease Progression , Brain/diagnostic imaging , Biomarkers/cerebrospinal fluid
16.
Hum Vaccin Immunother ; 20(1): 2334917, 2024 Dec 31.
Article in English | MEDLINE | ID: mdl-38584121

ABSTRACT

Rubella is a major cause of congenital defects, and the presence of rubella infection in a pregnant woman may lead to fetal death or congenital defects known as congenital rubella syndrome(CRS). Since China has not yet established a national CRS surveillance system, the true incidence cannot be determined. To understand the disease burden and epidemiological characteristics of CRS cases in China, the article reports the first case of CRS in Quzhou, China, and conducts a retrospective analysis of related cases that have been reported in China over the past decade. Because the availability of rubella-containing vaccines (RCV) was not widespread in China before 2008, women of childbearing age born before 2008 are generally unvaccinated against RCV. Due to the lack of routine CRS monitoring and screening, CRS is underreported in China. Vaccination of nonimmune women of childbearing age with RCV and establishing a sensitive and timely case-based CRS surveillance system can accelerate the elimination of rubella and CRS.


Subject(s)
Rubella Syndrome, Congenital , Rubella , Pregnancy , Humans , Female , Infant , Rubella Syndrome, Congenital/epidemiology , Rubella Syndrome, Congenital/prevention & control , Retrospective Studies , Rubella/epidemiology , Rubella/prevention & control , Rubella Vaccine , Rubella virus
18.
Ann Neurol ; 95(6): 1112-1126, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38551149

ABSTRACT

OBJECTIVE: Specific human leucocyte antigen (HLA) alleles are not only associated with higher risk to develop multiple sclerosis (MS) and other autoimmune diseases, but also with the severity of various viral and bacterial infections. Here, we analyzed the most specific biomarker for MS, that is, the polyspecific intrathecal IgG antibody production against measles, rubella, and varicella zoster virus (MRZ reaction), for possible HLA associations in MS. METHODS: We assessed MRZ reaction from 184 Swiss patients with MS and clinically isolated syndrome (CIS) and 89 Swiss non-MS/non-CIS control patients, and performed HLA sequence-based typing, to check for associations of positive MRZ reaction with the most prevalent HLA alleles. We used a cohort of 176 Swedish MS/CIS patients to replicate significant findings. RESULTS: Whereas positive MRZ reaction showed a prevalence of 38.0% in MS/CIS patients, it was highly specific (97.7%) for MS/CIS. We identified HLA-DRB1*15:01 and other tightly linked alleles of the HLA-DR15 haplotype as the strongest HLA-encoded risk factors for a positive MRZ reaction in Swiss MS/CIS (odds ratio [OR], 3.90, 95% confidence interval [CI] 2.05-7.46, padjusted = 0.0004) and replicated these findings in Swedish MS/CIS patients (OR 2.18, 95%-CI 1.16-4.02, padjusted = 0.028). In addition, female MS/CIS patients had a significantly higher probability for a positive MRZ reaction than male patients in both cohorts combined (padjusted <0.005). INTERPRETATION: HLA-DRB1*15:01, the strongest genetic risk factor for MS, and female sex, 1 of the most prominent demographic risk factors for developing MS, predispose in MS/CIS patients for a positive MRZ reaction, the most specific CSF biomarker for MS. ANN NEUROL 2024;95:1112-1126.


Subject(s)
Immunoglobulin G , Multiple Sclerosis , Humans , Female , Male , Multiple Sclerosis/genetics , Multiple Sclerosis/immunology , Multiple Sclerosis/cerebrospinal fluid , Immunoglobulin G/blood , Adult , Middle Aged , Herpesvirus 3, Human/immunology , Herpesvirus 3, Human/genetics , HLA-DRB1 Chains/genetics , Sweden/epidemiology , Cohort Studies , Young Adult , Rubella virus/genetics , Rubella virus/immunology , HLA Antigens/genetics , Antibodies, Viral/cerebrospinal fluid , Antibodies, Viral/blood , Alleles , Switzerland/epidemiology
19.
mBio ; 15(3): e0237323, 2024 Mar 13.
Article in English | MEDLINE | ID: mdl-38334805

ABSTRACT

Rubella virus (RuV) is an enveloped plus-sense RNA virus and a member of the Rubivirus genus. RuV infection in pregnant women can lead to miscarriage or an array of severe birth defects known as congenital rubella syndrome. Novel rubiviruses were recently discovered in various mammals, highlighting the spillover potential of other rubiviruses to humans. Many features of the rubivirus infection cycle remain unexplored. To promote the study of rubivirus biology, here, we generated replication-competent recombinant VSV-RuV (rVSV-RuV) encoding the RuV transmembrane glycoproteins E2 and E1. Sequencing of rVSV-RuV showed that the RuV glycoproteins acquired a single-point mutation W448R in the E1 transmembrane domain. The E1 W448R mutation did not detectably alter the intracellular expression, processing, glycosylation, colocalization, or dimerization of the E2 and E1 glycoproteins. Nonetheless, the mutation enhanced the incorporation of RuV E2/E1 into VSV particles, which bud from the plasma membrane rather than the RuV budding site in the Golgi. Neutralization by E1 antibodies, calcium dependence, and cell tropism were comparable between WT-RuV and either rVSV-RuV or RuV containing the E1 W448R mutation. However, the E1 W448R mutation strongly shifted the threshold for the acid pH-triggered virus fusion reaction, from pH 6.2 for the WT RuV to pH 5.5 for the mutant. These results suggest that the increased resistance of the mutant RuV E1 to acidic pH promotes the ability of viral envelope proteins to generate infectious rVSV and provide insights into the regulation of RuV fusion during virus entry and exit.IMPORTANCERubella virus (RuV) infection in pregnant women can cause miscarriage or severe fetal birth defects. While a highly effective vaccine has been developed, RuV cases are still a significant problem in areas with inadequate vaccine coverage. In addition, related viruses have recently been discovered in mammals, such as bats and mice, leading to concerns about potential virus spillover to humans. To facilitate studies of RuV biology, here, we generated and characterized a replication-competent vesicular stomatitis virus encoding the RuV glycoproteins (rVSV-RuV). Sequence analysis of rVSV-RuV identified a single-point mutation in the transmembrane region of the E1 glycoprotein. While the overall properties of rVSV-RuV are similar to those of WT-RuV, the mutation caused a marked shift in the pH dependence of virus membrane fusion. Together, our studies of rVSV-RuV and the identified W448R mutation expand our understanding of rubivirus biology and provide new tools for its study.


Subject(s)
Abortion, Spontaneous , Vaccines , Vesicular Stomatitis , Humans , Female , Pregnancy , Animals , Mice , Rubella virus/metabolism , Point Mutation , Glycoproteins/genetics , Viral Envelope Proteins/genetics , Vesiculovirus/genetics , Mammals/metabolism
20.
J Clin Microbiol ; 62(2): e0133923, 2024 Feb 14.
Article in English | MEDLINE | ID: mdl-38275299

ABSTRACT

Measles and rubella serological diagnoses are done by IgM detection. The World Health Organization Global Measles and Rubella Laboratory Network previously endorsed Siemens Enzygnost enzyme-linked immunosorbant assay kits, which have been discontinued. A recommended replacement has not been determined. We aimed to search for suitable replacements by conducting a systematic review and meta-analysis of IgM detection methods that are currently available for measles and rubella. A systematic literature search was performed in Medline, Embase, Global Health, Cochrane Central, and Scopus on March 22 and on 27 September 2023. Studies reporting measles and/or rubella IgM detection with terms around diagnostic accuracy were included. Risk of bias was assessed using QUADAS tools. Meta-DiSc and R were used for statistical analysis. Clinical samples totalling 5,579 from 28 index tests were included in the measles meta-analysis. Sensitivity and specificity of the individual measles studies ranged from 0.50 to 1.00 and 0.53 to 1.00, respectively. Pooled sensitivity and specificity of all measles IgM detection methods were 0.94 (CI: 0.90-0.97) and 0.94 (CI: 0.91-0.97), respectively. Clinical samples totalling 4,983 from 15 index tests were included in the rubella meta-analysis. Sensitivity and specificity of the individual rubella studies ranged from 0.78 to 1.00 and 0.52 to 1.00, respectively. Pooled sensitivity and specificity of all rubella IgM detection methods were 0.97 (CI: 0.93-0.98) and 0.96 (CI: 0.93-0.98), respectively. Although more studies would be ideal, our results may provide valuable information when selecting IgM detection methods for measles and/or rubella.


Subject(s)
Antibodies, Viral , Immunoglobulin M , Measles virus , Measles , Rubella virus , Rubella , Sensitivity and Specificity , Serologic Tests , Humans , Rubella/diagnosis , Measles/diagnosis , Rubella virus/immunology , Measles virus/immunology , Measles virus/isolation & purification , Immunoglobulin M/blood , Antibodies, Viral/blood , Serologic Tests/methods , Serologic Tests/standards , Reagent Kits, Diagnostic/standards
SELECTION OF CITATIONS
SEARCH DETAIL